5 recruiting, 2 active not recruiting, 2 completed, 1 not yet recruiting. 8 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Active not recruiting 2, Recruiting 2, Completed 1, Not yet recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 6 | Recruiting 3, Active not recruiting 1, Terminated 1, Unknown 1 |
Follow DIPG: new trials by email Literature Review of DIPG trials Research Report on DIPG
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Blood-Brain Barrier Disruption Using Exablate Magnetic Resonance-Guided Low Intensity Focused Ultrasound With Microbubbles in Combination With T-Cell Infusion in Patients With Newly Diagnosed Diffuse Midline Glioma (LIFT) TAA-T Cell, BBB Disruption - DMG, DIPG | Phase 1 | Recruiting | Children's National Research Institute | 45 | 2026-10-01 | 2026-10-16 |
| Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG). BCB-276 - Diffuse Intrinsic Pontine Glioma, DIPG | Phase 2 | Recruiting | BrainChild Bio, Inc | 75 | 2026-09-04 | 2026-10-28 |
| Gallium Maltolate for the Treatment of Pediatric Patients With Relapsed or Refractory Pediatric High-Grade Glioma and Atypical Teratoid Rhabdoid Tumor Gallium maltolate - High Grade Gliomas, Atypical Teratoid Rhabdoid Tumors (ATRT) | Phase 1 | Not yet recruiting | Sarah Rumler | 15 | 2026-05-15 | 2026-01-09 |
| Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). Olaparib; 177Lu-DOTATATE - Solid Tumor Cancer, Medulloblastoma | Phase 1 / Phase 2 | Recruiting | Fundación de investigación HM | 25 | 2024-09-20 | 2026-06-04 |
| xPedite: A Study to Expedite DIPG and DMG Research Oncology, DIPG | Recruiting | xCures | 400 | 2023-11-01 | 2024-04-30 | |
| 131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma 131I-Omburtamab, Convention Enhanced Delivery - DIPG | Phase 1 | Withdrawn | Y-mAbs Therapeutics | 2022-03-01 | 2023-06-26 | |
| INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas INCB7839 - Glioblastoma Multiforme, Anaplastic Astrocytoma | Phase 1 | Completed | Pediatric Brain Tumor Consortium | 13 | 2020-07-27 | 2026-10-01 |
| HRQL and Symptom Assessment for Patients With DIPG or Recurrent and Re-irradiated Brain Tumours and Their Caregivers This study does not include an intervention. - DIPG, Brain Tumor, Pediatric, Recurrent | Completed | University of Calgary | 20 | 2020-07-02 | 2026-04-15 | |
| A Study of Low Dose Bevacizumab With Conventional Radiotherapy Alone in Diffuse Intrinsic Pontine Glioma Bevacizumab Injection, Ultra-low-dose RT - DIPG | Phase 2 | Recruiting | Tata Memorial Centre | 40 | 2020-02-04 | 2025-04-11 |
| Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas CLR 131 - Pediatric Solid Tumor, Pediatric Lymphoma | Phase 1 | Active not recruiting | Cellectar Biosciences, Inc. | 30 | 2019-04-30 | 2026-10-01 |
| Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma Doxorubicin - Glioblastoma (GBM), DIPG | Phase 2 | Terminated | Meyer Children's Hospital IRCCS | 21 | 2016-02-01 | 2021-02-09 |
| Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma MDV9300 - DIPG | Phase 1 / Phase 2 | Unknown | Hadassah Medical Organization | 50 | 2014-02-01 | 2016-09-13 |
| A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas Mebendazole, Vincristine, Carboplatin - Pilomyxoid Astrocytoma, Pilocytic Astrocytoma | Phase 1 / Phase 2 | Active not recruiting | Julie Krystal | 10 | 2013-10-22 | 2026-08-06 |
Diffuse Intrinsic Pontine Glioma (7) · Glioma (6) · Glioblastoma (5) · Astrocytoma (3) · Brain Neoplasms (3) · Recurrence (3) · Ependymoma (2) · Gliosarcoma (2) · Medulloblastoma (2) · Neoplasms (2) · Neoplasms, Neuroepithelial (2) · Neuroblastoma (2) · Osteosarcoma (2) · Rhabdoid Tumor (2) · Sarcoma, Synovial (2)
Neoplasms by Histologic Type (9) · Neoplasms, Germ Cell and Embryonal (9) · Neoplasms, Glandular and Epithelial (9) · Neoplasms, Nerve Tissue (9) · Neuroectodermal Tumors (9) · Neoplasms by Site (8) · Nervous System Diseases (8) · Nervous System Neoplasms (8) · Brain Diseases (7) · Brain Stem Neoplasms (7) · Central Nervous System Diseases (7) · Central Nervous System Neoplasms (7) · Infratentorial Neoplasms (7) · Neoplasms (7) · Neoplasms, Neuroepithelial (7)
Bevacizumab (2) · CLR1404 (1) · Carboplatin (1) · Doxorubicin (1) · Irinotecan (1) · Mebendazole (1) · Temozolomide (1) · Vincristine (1) · gallium maltolate (1) · lutetium Lu 177 dotatate (1) · olaparib (1) · omburtamab I-131 (1) · pidilizumab (1)
BrainChild Bio, Inc (1) · Cellectar Biosciences, Inc. (1) · Children's National Research Institute (1) · Fundación de investigación HM (1) · Hadassah Medical Organization (1) · Julie Krystal (1) · Meyer Children's Hospital IRCCS (1) · Pediatric Brain Tumor Consortium (1) · Sarah Rumler (1) · Tata Memorial Centre (1) · University of Calgary (1) · Y-mAbs Therapeutics (1) · xCures (1)
United States (6) · Canada (2) · Australia (1) · India (1) · Israel (1) · Italy (1) · Spain (1)
Cori Abikoff, MD (1) · Derek Tsang, MD (1) · Fiona Schulte, PhD (1) · Jarrod Longcor (1) · Julie Krystal, MD (1) · Luca Szalontay, MD (1) · Mark Shapiro, PhD (1) · Marta Osuna Marco, PhD (1) · Michelle Monje, MD, PhD (1) · Rahul Krishnatry, Dr (1)
2015 (1), UM1CA081457 (1)